Indegene is a digital-first partner that helps pharmaceutical, biotech, and medical device companies commercialize their products and manage their medical operations, operating not as an IT vendor but as a strategic extension of the revenue-generating and regulatory functions of its clients. Founded in 1998 in Bengaluru and built on the principle that a medical doctor and a data scientist work side-by-side, the company has spent 27 years embedding itself into the commercial and medical workflows of the world’s largest drugmakers, absorbing each wave of technology-from digital platforms in the 2000s to AI a decade ago and now Generative AI-directly into how it delivers outcomes. Its recurring approach is to act as a “revenue partner, not a cost partner,” pricing its work on outcomes rather than effort, which means every efficiency gain from technology flows straight to its own bottom line and aligns its incentives with client growth. # Business segments Four engines at different stages of maturity-a large commercial outsourcing business, a fast-growing medical and regulatory unit, a brand-level agency challenger, and a nascent clinical-trials practice-all powered by a shared AI and technology backbone. ## 1. Enterprise Commercial Solutions: where the group’s scale and client relationships are built **It runs the sales and marketing operations for the world’s top drugmakers through multi-year, outcome-priced contracts, using GenAI to compress campaign timelines from months to days.** - **A share of the marketing budget, not the IT budget** - the engine addresses the roughly 35% of the estimated USD 176 billion in life sciences operations spend that goes to sales and marketing, and it sells to Chief Marketing Officers and brand heads, not the CIO organization. - **GenAI rewrites the production clock** - its Content Super App, an agentic platform, has demonstrated the ability to compress the creation of scientific briefs and near-final creative concepts from three months down to three days, a speed advantage that traditional agencies cannot match. - **Bought upstream creativity and downstream data** - the acquisition of agency CultHealth added brand-strategy and creative capabilities, while the USD 106 million purchase of BioPharm brought data-driven healthcare-provider targeting; the strategy is to merge the two into single, larger engagements that capture more of the client’s total marketing spend. - **Paid for outcomes, not hours** - the predominant pricing model is “managed-outcome,” meaning clients pay for results rather than effort, which gives Indegene a structural incentive to deploy AI faster than competitors still billing by the hour. ## 2. Enterprise Medical Solutions: the non-discretionary, regulation-driven engine **It consolidates the complex medical, safety, and regulatory workflows of pharmaceutical companies into technology-enabled global centers, making it a stable counterpart to the commercial business.** - **Work that cannot be cut** - spending on pharmacovigilance, regulatory affairs, and medical writing is described as non-discretionary for clients, so the revenue base remains stable even when drugmakers trim other budgets. - **From human review to “Human-less MLR”** - the company is targeting a Medical-Legal-Regulatory review process with sub-24-hour cycle times and a “One-Click Submissions” system aiming for an 85% reduction in submission time, reimagining workflows that have historically been slow and manual. - **Medical doctors and PhDs on the payroll** - the engine’s Centers of Excellence are staffed with multidisciplinary teams including physicians and pharmacologists, which is why it competes against contract research organizations (CROs) rather than IT services firms. - **Medical writing scaled through acquisition** - the purchase of Trilogy Writing & Consulting GmbH, a German firm with operations across Europe and North America, strengthened a capability that is now being augmented by an AI-powered Medical Writing Platform active across multiple clients. ## 3. Brand Activation: the agency challenger at the individual brand level **It runs digital marketing campaigns for specific drugs in specific countries, using AI to take market share from traditional advertising agencies.** - **One brand, one country** - unlike the enterprise-wide deals of the larger engines, these engagements are at the level of an individual drug or therapeutic area, primarily in the US and a few Western European countries. - **Two million HCPs in a data model** - the Invisage platform combines data on two million healthcare professionals and 200 million interactions with AI-driven scientific modeling to build hyper-personalized marketing campaigns, a precision that generalist agencies lack. - **The “agency-less model”** - Indegene is pursuing AI-led modular solutions that replace the traditional fragmented agency structure, and its Tectonic offering, which combines GenAI with creative expertise, had already secured five customers by the end of FY26. ## 4. Enterprise Clinical Solutions: the early-stage bet on modernizing trials **It is building a practice to streamline clinical trial design, patient recruitment, and real-world evidence generation, targeting a USD 36 billion addressable market.** - **From trial design to real-world data** - the engine’s solutions span clinical trial design consulting, patient recruitment, trial management, and real-world evidence generation, covering the full clinical operations spectrum. - **Partnerships as the entry path** - a strategic collaboration with Microsoft uses Microsoft Fabric for clinical-trial data management and analytics, while a partnership with CliniOps brings a patented platform for hybrid and decentralized trials, giving Indegene technology it does not need to build from scratch. - **A small base with a long runway** - the engine sits within the “Others” segment, which accounted for roughly 4% of revenue, but the company is already piloting a Global Innovation Centre model with a mid-sized pharma to use GenAI for accelerating FDA submissions. # Technology platforms and AI capability **A cross-cutting engine of 650 technologists and a decade of AI investment, embedded into every segment so that GenAI is not a product sold to clients but the way all work gets done.** - **Cortex codifies 25 years of know-how** - the flagship GenAI platform is a life sciences-specific knowledge engineering and multi-agent orchestration system that turns the company’s accumulated subject-matter expertise into advanced knowledge graphs, configurable with any large language model. - **Revenue per employee tells the story** - at approximately USD 75,000 per annum, up from USD 56,000 three years prior, the company claims the highest revenue-per-employee in the tech-led solutions industry, a direct result of embedding AI into delivery rather than selling it as a separate line item. - **A dual strategy of embedding and expanding** - GenAI is deployed by both embedding new features into existing platforms like the NEXT suite and building entirely new GenAI-first products for reimagined workloads, from adverse-event management to regulatory submissions planning. - **Microsoft as the cloud foundation** - a strategic collaboration announced in mid-2024 commits both companies to co-innovate GenAI services across commercial, medical, regulatory, and clinical functions, with the Content Super App running on Azure OpenAI Service. # Group structure and partners **A parent company in India with a web of 21 subsidiaries across North America, Europe, and Asia, built through 14 acquisitions that have added creative agencies, medical-writing firms, and data-capability platforms.** - **Ireland is the European hub** - Indegene Ireland Limited serves as the acquisition vehicle for European deals, with the board approving up to EUR 8.5 million in investment for business expansion, and it is a wholly owned subsidiary of Indegene Limited. - **Acquisitions fill capability gaps** - the Trilogy group brought medical writing, CultHealth and the MJL Group added agency and brand-activation skills, BioPharm contributed downstream data and targeting, and Warn And Co strengthened consulting, while the Cake Group in the DACH region was agreed for acquisition in late 2025. - **Partners extend the technology reach** - beyond the Microsoft collaboration, a partnership with CliniOps provides a platform for hybrid and decentralized clinical trials, and a collaboration with the Indian Institute of Science supports laboratory research into cardiovascular and neurodegenerative diseases.